Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q1 FY2015 Earnings Presentation
21 slides from Daiichi Sankyo's earnings presentation, Jul 31, 2015
Slide 1: Results Briefing: Results for Q1 FY2015
Results Briefing Results for Q1 FY2015 (April 1 – June 30, 2015) DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO July 31, 2015
Slide 2: Today's Topics
Today’s Topics FY2015 Q1 Results FY2015 revised consolidated forecast Edoxaban update R&D Topics 1
Slide 3: FY2015 Q1 Results
FY2015 Q1 Results 2
Slide 4: Overview of FY2015 Q1 Results
Overview of FY2015 Q1 Results (JPY Bn) FY2014 FY2015 YoY Q1 Results *1 Q1 Results +11.6% Revenue 213.7 238.4 +24.7 Cost of Sales 64.6 74.0 +9.4 SG&A Expenses 74.9 71.6 -3.3 R&D Expenses 41.4 43.7 +2.3 +49.8% Operating Profit 32.8 49.1 +16.3 Profit before tax 32.7 45.2 +12.5 +61.9% Profit attributabl
Slide 5: FY2015 Q1 Revenue
Positive Negative FY2015 Q1 Revenue Factors Factors Increased by 24.7 JPY Bn Decline in Daiichi Sankyo Inc. and Daiichi Sankyo Europe offsetted by growth of Japan, Luitpold and ASCA with Forex （JPY Bn） FY2014 Results 213.7 Japan Positive： Nexium +3.8 Memary +2.4 Japan (incl. Vaccines, OTC) 7.0 Lixan
Slide 6: FY2015 Q1 Operating Profit
Positive Negative FY2015 Q1 Operating Profit Factors Factors Increased by 16.3 JPY Bn due to increased revenue and decreased R&D and SG&A expenses absorbing increased cost of sales and forex impact （JPY Bn） FY2014 Results 32.8 Revenue +24.7 Revenue 32.8 24.7 incl. forex impact 12.4 Cost of Sales 8.6
Slide 7: FY2015 Q1 Profit attributable to owners of the Company
FY2015 Q1 Profit Positive Negative Factors Factors attributable to owners of the Company Increased by 13.4 JPY Bn due to increased operating profit Expenses relating to the sales of the Sun Pharma shares is booked as financial expenses （JPY Bn） FY2014 Results 21.6 Operating Profit 16.3 Financial Inc
Slide 8: Major business units
Major business units （JPY Bn） FY2014 FY2015 vs. Forecast YoY Q1 Results Q1 Results (%) Japan 108.0 114.2 +6.2 23% Daiichi Sankyo Healthcare 9.4 10.8 +1.4 23% Daiichi Sankyo Inc. 41.6 48.0 +6.4 29% Olmesartan 25.7 28.8 +3.1 29% Welchol 11.3 13.5 +2.2 37% Effient 4.2 5.2 +1.0 - Savaysa - -0.3 -0.3 - M
Slide 9: Major products in Japan
Major products in Japan （JPY Bn） FY2014 FY2015 vs. Forecast YoY Q1 Results Q1 Results (%) Olmetec anti-hypertension 18.7 18.5 -0.3 23% anti-ulcer Nexium （Proton Pump Inhibitor） 15.3 19.1 +3.8 26% Memary treatment for Alzheimer 7.9 10.2 +2.4 22% analgesic and anti- Loxonin inflammatory 12.2 12.6 +0.3
Slide 10: FY2015 revised consolidated forecast
FY2015 revised consolidated forecast 9
Slide 11: FY2015 revised consolidated forecast
FY2015 revised consolidated forecast (JPY Bn) FY 2015 FY 2015 vs. Original Forecast Revised Forecast Original （May） （July） Forecast Due to delay of launch of Revenue 920.0 950.0 +30.0 GE products for Welchol and further expansion in some products including Cost of Sales 300.0 302.0 +2.0 Injectafer S
Slide 12: Summary of revised revenue forecast
Summary of revised revenue forecast (JPY Bn) FY 2015 FY 2015 Original Revised vs. Original Forecast Forecast Forecast Sales forecast in Japan （May） （July） remains the same as May, although some products has Japan 488.0 488.0 - been revised Olmetec 80.0 79.0 -1.0 Cravit 21.0 17.0 -4.0 Welchol; Due to
Slide 13: Edoxaban update
Edoxaban update 12
Slide 14: Edoxaban update
Edoxaban update Launch and development for making Edoxaban a flagship product after olmesartan Global sales forecast in FY2015: 14.7 JPY Bn JPN • Making a good start (especially in VTE) • Revised sales forecast (5.0 JPY Bn→11.0 JPY Bn) US • Negotiation with payers to be listed in formularies of
Slide 15: R&D Topics
Daiichi-Sankyo 14
Slide 16: Major R&D pipeline
Major R&D pipeline As of July 2015 Therapeutic area Phase 1 Phase 2 Phase 3 Application DS-1040 CS-3150 (JP) Prasugrel (JP) Edoxaban (ASCA) (Acute ischemic stroke / TAFIa (Hypertension ・ DM nephropathy / (CS-747 / ischemic stroke / anti- (DU-176b / AF / oral factor Xa inhibitor) Cardiovascul
Slide 17: Update on major late phase products: PLX3397
Update on major late phase products PLX3397: FMS/KIT/FLT3-ITD inhibitor Initiated new clinical trials Tenosynovial Giant Cell Tumor (TGCT) Phase 3 study Initiated in May 2015 Result of the Phase 1 study was published in NEJM in July 2015 12 out of 23 patients (52 %) achieved a partial respon
Slide 18: Update on major late stage products: Quizartinib
Update on major late stage products Quizartinib: FLT3-ITD inhibitor QuANTUM-R* Phase 3 study in progress * Quizartinib Advancement into the Next Generation of Trial for Unmet Needs in AML Second-line therapy for relapsed or refractory FLT3-ITD-positive acute myeloid Leukemia Determine overall su
Slide 19: Update on major late stage products: CL-108
Update on major late stage products CL-108*： Hydrocodone combination with less Opioid-Induced Nausea and Vomiting, OINV Phase 3 studies on track, NDA in FY2015 Novel, bi-layered tablet provides anti-emetic activity prior to hydrocodone effect Hydrocodone 7.5 mg / Acetaminophen 325 mg + Promethazin
Slide 20: Update on major late stage products: Mirogabalin
Update on major late stage products Mirogabalin: α2δ ligand Phase 3 studies in each region : on track US/EU: Fibromyalgia Three phase 3 studies for fibromyalgia: in progress NDA: targeted for FY2017 Approval: targeted for FY2019 JP/Asia: Peripheral Neuropathic Pain Phase 3 studies for diab
Slide 21: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f
Daiichi Sankyo Company — Q1 FY2015 Earnings Presentation on 6ix